Company Overview and News
August marks the 10th month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $1,665.95.
SOJA GIS XOM IDCC SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI WLKP ENB ETP HP ORI SPG WPC ADM
2018-08-21 247wallst - 2
Stocks were indicated to open marginally higher on Tuesday, which would make a four-day Dow Jones industrials rally, if the gains hold. Earnings season is now about 90% of the way to its end, and more than 70% of the companies exceeded expectations. Still, investors have noted that the stock market volatility in 2018 has been less rewarding for those who have continued to buy on every dip than had been the case for several years.
HON SYMC DAVA ADP AJRD HON FN ADUS ADPVV AAPL ITW TRI EMR MS PAYX
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
Document UNITED STATES
2018-08-08 investorplace - 2
Investing for income usually results in quieter, and lower-risk, investment strategies. The best dividend stocks tend to be more mature and lower-growth, which is why they distribute cash to shareholders rather than reinvesting it in their businesses. The goal of most income investors is to protect principal by buying quality companies who will grow dividends over time, rather than chasing ‘hot’ stocks with higher risk.
IBM HON GE F GEC ETH SCS ABB MAT AMZN FTRPR HON MLHR ABLZF TSLA GNE SPG EMR KNL SSI GMAN MAC FTR
2018-07-27 investorplace - 4
With automated technologies, the domain of fantasy and science-fiction is steadily becoming not only reality, it’s becoming the new norm. The robotic revolution has dramatically altered the economic landscape, driving productivity primarily in manufacturing and in many other sectors. As a result, automation stocks are virtual necessities for your portfolio.
LMT MIDD A CGNX CTRL ISRG EKSO ABB TER HON AAPL EMR OII BRKS ROK
2018-07-17 investorplace - 1
As an investment sector, the Internet of Things, or IoT, is a no-brainer. Increasingly, our consumer devices no longer have a specific function or operation; rather, they’re part of an integrated, digital ecosystem that responds to variable requests. This movement will only increase in volume and engagement, but picking the right IoT stock can be a challenge.
ADT FIT HON MU GRMN AAPL ADI EMR JCI INTC NTGR
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA GIS XOM IDCC SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP HP ORI SPG WPC ADM
The World Cup began in 1930. After a 12-year break due to World War II, the soccer — oops, fútbol — tournament has been played every four years since 1950. This weekend we watched France beat Croatia 4-2 to win the 2018 World Cup. But it got us thinking, what about a World Cup for dividend stocks?
LOW PG PH AWR GPC NYTAB CL JNJ NWN KO DOV EMR MMM
In the first article of this series, the current interest rate environment was described as it impacts significantly long-term investments being made today in that environment.
LOW FRT JNJ ADP KO BEN GPC EMR SPG ED MCD
10h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
10h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
12h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to EMR / Emerson Electric Co. on message board site Silicon Investor.
as of ET